J. Goldman & Co LP Makes New Investment in Heron Therapeutics, Inc. (NASDAQ:HRTX)

J. Goldman & Co LP purchased a new position in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 270,100 shares of the biotechnology company's stock, valued at approximately $413,000. J. Goldman & Co LP owned 0.18% of Heron Therapeutics at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its stake in Heron Therapeutics by 295.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 206,711 shares of the biotechnology company's stock worth $411,000 after purchasing an additional 154,487 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Heron Therapeutics in the 4th quarter worth approximately $208,000. Principal Financial Group Inc. boosted its stake in Heron Therapeutics by 10.6% in the 4th quarter. Principal Financial Group Inc. now owns 113,560 shares of the biotechnology company's stock worth $174,000 after purchasing an additional 10,909 shares in the last quarter. Bridgeway Capital Management LLC acquired a new stake in Heron Therapeutics in the 4th quarter worth approximately $459,000. Finally, Wells Fargo & Company MN boosted its stake in Heron Therapeutics by 22.2% in the 4th quarter. Wells Fargo & Company MN now owns 74,763 shares of the biotechnology company's stock worth $114,000 after purchasing an additional 13,568 shares in the last quarter. Hedge funds and other institutional investors own 80.01% of the company's stock.

Heron Therapeutics Trading Up 8.7%

HRTX traded up $0.15 during midday trading on Thursday, hitting $1.87. 1,893,196 shares of the company were exchanged, compared to its average volume of 2,334,260. The company's 50 day simple moving average is $2.15 and its 200 day simple moving average is $1.82. The firm has a market capitalization of $285.29 million, a price-to-earnings ratio of -10.39 and a beta of 1.33. Heron Therapeutics, Inc. has a 1-year low of $1.04 and a 1-year high of $3.93.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.02. The company had revenue of $38.90 million for the quarter, compared to analyst estimates of $37.08 million. On average, equities analysts anticipate that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Needham & Company LLC restated a "buy" rating and issued a $4.00 price objective on shares of Heron Therapeutics in a research note on Friday, April 11th. StockNews.com cut shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, March 8th.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.